Anti-inflammatory Dietary Intervention in Overweight and Obese Adolescents
NCT ID: NCT01665742
Last Updated: 2014-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
58 participants
INTERVENTIONAL
2012-01-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Anti-inflammatory supplement
8-weeks of daily supplementation with:
1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene
in conjunction with a weight management programme
Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene
1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks
AND
4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks
in conjunction with a weight management programme
Placebo supplement
8 weeks of daily supplementation with:
1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets
in conjunction with a weight management programme
Placebo supplement
1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks
AND
4 x film-coated placebo tablets daily for 8 weeks
in conjunction with a weight management programme
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene
1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks
AND
4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks
in conjunction with a weight management programme
Placebo supplement
1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks
AND
4 x film-coated placebo tablets daily for 8 weeks
in conjunction with a weight management programme
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 13-18 years
3. Body mass index ≥ 91st percentile on UK growth reference charts (Cole, 1995)
4. Medications/dietary supplements which do not interfere with the intervention are allowed, on condition that the participants adhere to the same regimen during the intervention, including oral contraceptives and other non-fatty acid based dietary supplements (e.g. garlic)
5. Smoker or non-smoker
6. Not participating in any other intervention study
Exclusion Criteria
2. Endocrine disorders such as Polycystic Ovary Syndrome
3. Currently on treatment for a chronic inflammatory condition such as asthma
4. Kidney or liver dysfunction
5. Iron deficiency anaemia
6. Prescribed anti-inflammatory medication
7. Consumers of fatty acid supplements including fish oils, evening primrose oil and antioxidant vitamin (A, C, E, -carotene) supplements
8. High consumers of oily fish (\> 2 servings/week)
9. Participants planning to start a special diet or lose weight (e.g. Slimfast, Atkins etc)
10. Weight change ≥3kg within the last 3 months
11. Alcohol or drug abuse (based on clinical judgement)
12. Participants with an allergy to fish and/or shellfish
13 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Children's Research Centre, Ireland
NETWORK
University of Dublin, Trinity College
OTHER
The Adelaide and Meath Hospital
OTHER
St. James's Hospital, Ireland
OTHER
University College Dublin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof Helen M Roche
Associate Professor of Nutrigenomics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen M Roche, BSc, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
University College Dublin
Fiona Lithander, BSc, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Dublin, Trinity College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adelaide and Meath Hospital, Incorporating the National Children's Hospital Dublin,
Dublin, , Ireland
Trinity Centre for Health Sciences, St, James's Hospital
Dublin, , Ireland
University College Dublin
Dublin, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McMorrow AM, Connaughton RM, Magalhaes TR, McGillicuddy FC, Hughes MF, Cheishvili D, Morine MJ, Ennis S, Healy ML, Roche EF, Tremblay RE, Szyf M, Lithander FE, Roche HM. Personalized Cardio-Metabolic Responses to an Anti-Inflammatory Nutrition Intervention in Obese Adolescents: A Randomized Controlled Crossover Trial. Mol Nutr Food Res. 2018 May;62(10):e1701008. doi: 10.1002/mnfr.201701008.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TNS-5
Identifier Type: -
Identifier Source: org_study_id